The Indian drug manufacturer will have exclusive rights to the vaccine in India during the term of the transaction and non-exclusive rights during the “pandemic period” in all countries other than those identified by the World Bank as upper middle or high income countries.
The deal was signed on July 30, according to SEC documentation from Novavax. https://bit.ly/3iggGQv
On Tuesday, Novavax announced that its experimental vaccine against COVID-19 produced high levels of antibodies against the new coronavirus in a small early-stage clinical trial and that it could begin a major phase III trial in late September.
(Report by Vishwadha Chander from Bengaluru; Editing by Devika Syamnath)